Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Antoniou

Showing results (181-190 of 395) with videos related to

Pageof 40
Sort By:
Journal of Medical Genetics|April 9, 2013
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer ConsortiumChristine Fischer, Karoline Kuchenbäcker, Christoph Engel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating GroupRichard M Brohet, David E Goldgar, Douglas F Easton, et al.
Breast Cancer Research : BCR|March 4, 2005
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Antonis C Antoniou, David L Duffy, et al.
The Lancet. Oncology|May 10, 2025
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health recordsHend Hassan, Isaac Allen, Tameera Rahman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 26, 2021
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL studyD Ioannides, N Antonakopoulos, S Georgiou, et al.
The Lancet Regional Health. Europe|May 15, 2024
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort studyIsaac Allen, Hend Hassan, Walburga Yvonne Joko-Fru, et al.
Journal of Medical Genetics|November 30, 2021
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factorsAndrew Lee, Xin Yang, Jonathan Tyrer, et al.
American Journal of Human Genetics|October 7, 2022
Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk predictionShuai Li, Robert J MacInnis, Andrew Lee, et al.
Journal of the National Cancer Institute|January 20, 2022
Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and BenefitsLieske H Schrijver, Thea M Mooij, Anouk Pijpe, et al.
Journal of Medical Genetics|September 26, 2022
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on <i>RAD51C</i>, <i>RAD51D</i>, <i>BARD1</i> updates to tumour pathology and cancer incidenceAndrew Lee, Nasim Mavaddat, Alex Cunningham, et al.
Pageof 40

Showing results (181-190 of 395) with videos related to

Sort By:
Pageof 40
Journal of Medical Genetics|April 9, 2013
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer ConsortiumChristine Fischer, Karoline Kuchenbäcker, Christoph Engel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating GroupRichard M Brohet, David E Goldgar, Douglas F Easton, et al.
Breast Cancer Research : BCR|March 4, 2005
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Antonis C Antoniou, David L Duffy, et al.
The Lancet. Oncology|May 10, 2025
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health recordsHend Hassan, Isaac Allen, Tameera Rahman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 26, 2021
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL studyD Ioannides, N Antonakopoulos, S Georgiou, et al.
The Lancet Regional Health. Europe|May 15, 2024
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort studyIsaac Allen, Hend Hassan, Walburga Yvonne Joko-Fru, et al.
Journal of Medical Genetics|November 30, 2021
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factorsAndrew Lee, Xin Yang, Jonathan Tyrer, et al.
American Journal of Human Genetics|October 7, 2022
Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk predictionShuai Li, Robert J MacInnis, Andrew Lee, et al.
Journal of the National Cancer Institute|January 20, 2022
Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and BenefitsLieske H Schrijver, Thea M Mooij, Anouk Pijpe, et al.
Journal of Medical Genetics|September 26, 2022
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on <i>RAD51C</i>, <i>RAD51D</i>, <i>BARD1</i> updates to tumour pathology and cancer incidenceAndrew Lee, Nasim Mavaddat, Alex Cunningham, et al.
Pageof 40